Cargando…

Vasopressin in vasoplegic shock: A systematic review

BACKGROUND: Vasoplegic shock is a challenging complication of cardiac surgery and is often resistant to conventional therapies for shock. Norepinephrine and epinephrine are standards of care for vasoplegic shock, but vasopressin has increasingly been used as a primary pressor in vasoplegic shock bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Andrew J, Seisa, Mohamed O, Nayfeh, Tarek, Wieruszewski, Patrick M, Nei, Scott D, Smischney, Nathan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754532/
https://www.ncbi.nlm.nih.gov/pubmed/33384951
http://dx.doi.org/10.5492/wjccm.v9.i5.88
_version_ 1783626216939454464
author Webb, Andrew J
Seisa, Mohamed O
Nayfeh, Tarek
Wieruszewski, Patrick M
Nei, Scott D
Smischney, Nathan J
author_facet Webb, Andrew J
Seisa, Mohamed O
Nayfeh, Tarek
Wieruszewski, Patrick M
Nei, Scott D
Smischney, Nathan J
author_sort Webb, Andrew J
collection PubMed
description BACKGROUND: Vasoplegic shock is a challenging complication of cardiac surgery and is often resistant to conventional therapies for shock. Norepinephrine and epinephrine are standards of care for vasoplegic shock, but vasopressin has increasingly been used as a primary pressor in vasoplegic shock because of its unique pharmacology and lack of inotropic activity. It remains unclear whether vasopressin has distinct benefits over standard of care for patients with vasoplegic shock. AIM: To summarize the available literature evaluating vasopressin vs non-vasopressin alternatives on the clinical and patient-centered outcomes of vasoplegic shock in adult intensive care unit (ICU) patients. METHODS: This was a systematic review of vasopressin in adults (≥ 18 years) with vasoplegic shock after cardiac surgery. Randomized controlled trials, prospective cohorts, and retrospective cohorts comparing vasopressin to norepinephrine, epinephrine, methylene blue, hydroxocobalamin, or other pressors were included. The primary outcomes of interest were 30-d mortality, atrial/ventricular arrhythmias, stroke, ICU length of stay, duration of vasopressor therapy, incidence of acute kidney injury stage II-III, and mechanical ventilation for greater than 48 h. RESULTS: A total of 1161 studies were screened for inclusion with 3 meeting inclusion criteria with a total of 708 patients. Two studies were randomized controlled trials and one was a retrospective cohort study. Primary outcomes of 30-d mortality, stroke, ventricular arrhythmias, and duration of mechanical ventilation were similar between groups. Conflicting results were observed for acute kidney injury stage II-III, atrial arrhythmias, duration of vasopressors, and ICU length of stay with higher certainty of evidence in favor of vasopressin serving a protective role for these outcomes. CONCLUSION: Vasopressin was not found to be superior to alternative pressor therapy for any of the included outcomes. Results are limited by mixed methodologies, small overall sample size, and heterogenous populations.
format Online
Article
Text
id pubmed-7754532
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-77545322020-12-30 Vasopressin in vasoplegic shock: A systematic review Webb, Andrew J Seisa, Mohamed O Nayfeh, Tarek Wieruszewski, Patrick M Nei, Scott D Smischney, Nathan J World J Crit Care Med Systematic Reviews BACKGROUND: Vasoplegic shock is a challenging complication of cardiac surgery and is often resistant to conventional therapies for shock. Norepinephrine and epinephrine are standards of care for vasoplegic shock, but vasopressin has increasingly been used as a primary pressor in vasoplegic shock because of its unique pharmacology and lack of inotropic activity. It remains unclear whether vasopressin has distinct benefits over standard of care for patients with vasoplegic shock. AIM: To summarize the available literature evaluating vasopressin vs non-vasopressin alternatives on the clinical and patient-centered outcomes of vasoplegic shock in adult intensive care unit (ICU) patients. METHODS: This was a systematic review of vasopressin in adults (≥ 18 years) with vasoplegic shock after cardiac surgery. Randomized controlled trials, prospective cohorts, and retrospective cohorts comparing vasopressin to norepinephrine, epinephrine, methylene blue, hydroxocobalamin, or other pressors were included. The primary outcomes of interest were 30-d mortality, atrial/ventricular arrhythmias, stroke, ICU length of stay, duration of vasopressor therapy, incidence of acute kidney injury stage II-III, and mechanical ventilation for greater than 48 h. RESULTS: A total of 1161 studies were screened for inclusion with 3 meeting inclusion criteria with a total of 708 patients. Two studies were randomized controlled trials and one was a retrospective cohort study. Primary outcomes of 30-d mortality, stroke, ventricular arrhythmias, and duration of mechanical ventilation were similar between groups. Conflicting results were observed for acute kidney injury stage II-III, atrial arrhythmias, duration of vasopressors, and ICU length of stay with higher certainty of evidence in favor of vasopressin serving a protective role for these outcomes. CONCLUSION: Vasopressin was not found to be superior to alternative pressor therapy for any of the included outcomes. Results are limited by mixed methodologies, small overall sample size, and heterogenous populations. Baishideng Publishing Group Inc 2020-12-18 /pmc/articles/PMC7754532/ /pubmed/33384951 http://dx.doi.org/10.5492/wjccm.v9.i5.88 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Systematic Reviews
Webb, Andrew J
Seisa, Mohamed O
Nayfeh, Tarek
Wieruszewski, Patrick M
Nei, Scott D
Smischney, Nathan J
Vasopressin in vasoplegic shock: A systematic review
title Vasopressin in vasoplegic shock: A systematic review
title_full Vasopressin in vasoplegic shock: A systematic review
title_fullStr Vasopressin in vasoplegic shock: A systematic review
title_full_unstemmed Vasopressin in vasoplegic shock: A systematic review
title_short Vasopressin in vasoplegic shock: A systematic review
title_sort vasopressin in vasoplegic shock: a systematic review
topic Systematic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754532/
https://www.ncbi.nlm.nih.gov/pubmed/33384951
http://dx.doi.org/10.5492/wjccm.v9.i5.88
work_keys_str_mv AT webbandrewj vasopressininvasoplegicshockasystematicreview
AT seisamohamedo vasopressininvasoplegicshockasystematicreview
AT nayfehtarek vasopressininvasoplegicshockasystematicreview
AT wieruszewskipatrickm vasopressininvasoplegicshockasystematicreview
AT neiscottd vasopressininvasoplegicshockasystematicreview
AT smischneynathanj vasopressininvasoplegicshockasystematicreview